Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc works on 2 rare diseases tracked on Trial Friend, including Cystic Fibrosis, Urea Cycle Disorders, with 2 recruiting clinical trials.
Arcturus Therapeutics is a commercial mRNA medicines and vaccines company developing therapies for liver and respiratory rare diseases. The company's platform technologies include STARR, a self-amplifying mRNA technology, and LUNAR, a lipid-mediated delivery system for therapeutic RNA and DNA to target cells.
Focus areas at Arcturus Therapeutics Holdings Inc
As a rare disease specialist, Arcturus Therapeutics Holdings Inc has active clinical trial programs and drug development efforts across 2 rare diseases, including Cystic Fibrosis, Urea Cycle Disorders. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Arcturus Therapeutics Holdings Inc, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Arcturus Therapeutics Holdings Inc is headquartered in San Diego, United States, founded in 2013, publicly traded under the ticker symbol ARCT. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Arcturus Therapeutics Holdings Inc Drug Pipeline
Arcturus Therapeutics Holdings Inc has 2 active clinical trials across 1 development stage, with 2 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Arcturus Therapeutics Holdings Inc Clinical Trials (2)
Active and recruiting clinical trials sponsored by Arcturus Therapeutics Holdings Inc, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Arcturus Therapeutics Holdings Inc. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Cystic Fibrosis. Turn any of these off from the link in every email.
FDA-Approved Drugs
Arcturus Therapeutics Holdings Inc Trial Locations
Arcturus Therapeutics Holdings Inc clinical trials are running at 14 sites in 1 country. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (2)
Diseases targeted by Arcturus Therapeutics Holdings Inc's clinical trial and drug development programs
Cystic fibrosis is an autosomal recessive genetic disorder affecting the CFTR protein, which normally regulates chloride transport. Defective CFTR causes thick, sticky secretions in the lungs and dige...
Urea Cycle Disorders (UCDs) are a group of genetic conditions affecting the enzymes that convert toxic ammonia to urea for excretion. Deficiency of any of the eight enzymes in the urea cycle leads to ...
Patient Resources
Organizations and resources related to Arcturus Therapeutics Holdings Inc's rare disease focus areas
Frequently Asked Questions About Arcturus Therapeutics Holdings Inc
Common questions about Arcturus Therapeutics Holdings Inc's rare disease programs, clinical trials, and treatments.